CTNM
Contineum Therapeutics, Inc.Company with tickers: CTNM
CIK
1855175
CUSIP
21217B100
Shares Outstanding
32,673,536
Price
Holdings
Short Volume
Short Interest
Fails to Deliver
SEC Filings
Earnings Calls
Insider Trading
Congress Trades
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2026-04-06 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-04-06 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 4,170 |
| 2026-03-02 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-03-02 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 4,170 |
| 2026-03-02 | Watkins Tim | CMO & Head of Development | Sell | 3,611 |
| 2026-03-02 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2026-03-02 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2026-02-25 | Stengone Carmine N. | Director | Sell | 2,700 |
| 2026-02-25 | Stengone Carmine N. | Director | Convert | 2,700 |
| 2026-02-25 | Stengone Carmine N. | Director | Convert | 2,700 |
| 2026-02-25 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 3,824 |
| 2026-02-25 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 3,824 |
| 2026-02-25 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 3,824 |
| 2026-02-24 | Stengone Carmine N. | Director | Convert | 4,400 |
| 2026-02-24 | Stengone Carmine N. | Director | Sell | 4,400 |
| 2026-02-24 | Stengone Carmine N. | Director | Convert | 4,400 |
| 2026-02-24 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 4,300 |
| 2026-02-24 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 4,300 |
| 2026-02-24 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-02-24 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 4,300 |
| 2026-02-19 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 100 |
| 2026-02-19 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 100 |
| 2026-02-19 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-02-19 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 100 |
| 2026-02-11 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 400 |
| 2026-02-11 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-02-11 | Lorrain Daniel S. | Chief Scientific Officer | Convert | 400 |
| 2026-02-11 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 400 |
| 2026-02-11 | Stengone Carmine N. | Director | Convert | 400 |
| 2026-02-11 | Stengone Carmine N. | Director | Convert | 400 |
| 2026-02-11 | Stengone Carmine N. | Director | Sell | 400 |
| 2026-02-03 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 3,000 |
| 2026-02-03 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-01-30 | Healy John Stephen | General Counsel and Corp Sec | Award | 206,411 |
| 2026-01-30 | Watkins Tim | CMO & Head of Development | Award | 160,000 |
| 2026-01-30 | Slover Peter T | Chief Financial Officer | Award | 192,000 |
| 2026-01-30 | Stengone Carmine N. | Director | Award | 445,000 |
| 2026-01-30 | Lorrain Daniel S. | Chief Scientific Officer | Award | 160,000 |
| 2026-01-28 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2026-01-28 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2026-01-28 | Watkins Tim | CMO & Head of Development | Sell | 2,800 |
| 2026-01-05 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2026-01-05 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 3,670 |
| 2025-12-29 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2025-12-29 | Watkins Tim | CMO & Head of Development | Convert | 3,611 |
| 2025-12-29 | Watkins Tim | CMO & Head of Development | Sell | 3,611 |
| 2025-12-23 | Lorrain Daniel S. | Chief Scientific Officer | Other | 6,842 |
| 2025-12-23 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 4,170 |
| 2025-06-26 | Boyce Sarah | Director | Award | 14,750 |
| 2025-06-26 | Schimmelpennink Evert B. | Director | Award | 14,750 |
| 2025-06-26 | Brady Todd R. | Director | Award | 14,750 |
| 2025-06-26 | Ignelzi Troy A. | Director | Award | 14,750 |
| 2025-06-26 | Miralles Gines Diego | Director | Award | 14,750 |
| 2025-06-26 | Lyons-Williams Lori | Director | Award | 14,750 |
| 2025-06-26 | Ware Olivia C | Director | Award | 14,750 |
| 2025-04-28 | Watkins Tim | CMO & Head of Development | Award | 260,000 |
| 2025-04-28 | Watkins Tim | CMO & Head of Development | Other | 0 |
| 2025-03-14 | Miralles Gines Diego | Director | Other | 0 |
| 2025-03-14 | Miralles Gines Diego | Director | Award | 29,500 |
| 2025-01-31 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Award | 110,000 |
| 2025-01-31 | Healy John Stephen | General Counsel and Corp Sec | Award | 63,589 |
| 2025-01-31 | Slover Peter T | Chief Financial Officer | Award | 110,000 |
| 2025-01-31 | Lorrain Daniel S. | Chief Scientific Officer | Award | 110,000 |
| 2025-01-31 | Stengone Carmine N. | Director | Award | 300,000 |
| 2024-11-25 | Lorrain Daniel S. | Chief Scientific Officer | Other | 3,898 |
| 2024-11-25 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 1,010 |
| 2024-11-18 | Lorrain Daniel S. | Chief Scientific Officer | Other | 3,898 |
| 2024-11-18 | Lorrain Daniel S. | Chief Scientific Officer | Sell | 6,091 |
| 2024-08-13 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Convert | 12,800 |
| 2024-08-13 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Convert | 12,800 |
| 2024-06-24 | Boyce Sarah | Director | Award | 29,500 |
| 2024-06-24 | Boyce Sarah | Director | Other | 0 |
| 2024-06-03 | Healy John Stephen | General Counsel and Corp Sec | Award | 160,000 |
| 2024-05-30 | Healy John Stephen | General Counsel and Corp Sec | Other | 0 |
| 2024-05-24 | Ignelzi Troy A. | Director | Award | 6,350 |
| 2024-05-24 | Lyons-Williams Lori | Director | Award | 29,500 |
| 2024-05-24 | Slover Peter T | Chief Financial Officer | Award | 100,000 |
| 2024-05-24 | Lorrain Daniel S. | Chief Scientific Officer | Award | 100,000 |
| 2024-05-24 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | Award | 100,000 |
| 2024-05-24 | Schimmelpennink Evert B. | Director | Award | 29,500 |
| 2024-05-24 | Stengone Carmine N. | Director | Award | 285,000 |
| 2024-05-24 | Ware Olivia C | Director | Award | 3,700 |
| 2024-05-24 | Brady Todd R. | Director | Award | 29,500 |
| 2024-05-20 | Ignelzi Troy A. | Director | Award | 23,150 |
| 2024-05-20 | Ignelzi Troy A. | Director | Other | 0 |
| 2024-04-09 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 70,498 |
| 2024-04-09 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 1,423,119 |
| 2024-04-09 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 298,975 |
| 2024-04-09 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 391,785 |
| 2024-04-09 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 22,312 |
| 2024-04-04 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 0 |
| 2024-04-04 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 0 |
| 2024-04-04 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 0 |
| 2024-04-04 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 375,535 |
| 2024-04-04 | Versant Venture Capital VI, L.P. | 10% Owner | Other | 0 |
| 2024-04-04 | Ware Olivia C | Director | Other | 0 |
| 2024-04-04 | Lorrain Daniel S. | Chief Scientific Officer | Other | 0 |
| 2024-04-04 | Lorrain Daniel S. | Chief Scientific Officer | Other | 175,762 |
| 2024-04-04 | Schimmelpennink Evert B. | Director | Other | 0 |
| 2024-04-04 | Lyons-Williams Lori | Director | Other | 0 |